Differences in microparticle release in patients with acute coronary syndrome and stable angina

Circulation Journal

Volumn 76, Issue 9, 2012, Pages 2174-2182

  Biasucci, Luigi Marzio ^a   Porto, Italo ^a   di Vito, Luca ^a   de Maria, Giovanni Luigi ^a   Leone, Antonio Maria ^a   Tinelli, Giovanni ^a   Tritarelli, Alessandra ^a   di Rocco, Giuliana ^a   Snider, Francesco ^a   Capogrossi, Maurizio C ^b   Crea, Filippo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b Vascular Pathology Laboratory   (Italy)

Author keywords

Acute coronary syndromes; C reactive protein; Microparticles; Stable angina; Troponin T

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CD31 ANTIGEN; CLOPIDOGREL; CREATINE KINASE; LOW MOLECULAR WEIGHT HEPARIN; TIROFIBAN; TROPONIN T;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROTIC PLAQUE; B SCAN; CONTROLLED STUDY; ENDOTHELIAL MICROPARTICLE; FEMALE; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMBRANE MICROPARTICLE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PLATELET MICROPARTICLE; PROSPECTIVE STUDY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; AGED; ANGINA, STABLE; ANNEXIN A5; APOPTOSIS; ATHEROSCLEROSIS; BLOOD PLATELETS; C-REACTIVE PROTEIN; CELL-DERIVED MICROPARTICLES; ENDOTHELIAL CELLS; FEMALE; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; TROPONIN T;

EID: 84865483194     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-0068     Document Type: Article

References (36)

1. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation 2005; 111: 3481-3488.
2. Diamant M, Tushuizen ME, Sturk A, Nieuwland R. Cellular microparticles: New players in the field of vascular disease? Eur J Clin Invest 2004; 34: 392-401.
3. Morel O, Toti F, Hugel B, Bakouboula B, Camoin-Jau L, Dignat-George F, et al. Procoagulant microparticles: Disrupting the vascular homeostasis equation? Arterioscler Thromb Vasc Biol 2006; 26: 2594-2604.
4. Breitenstein A, Tanner FC, Lüscher TF. Tissue factor and cardiovascular disease: Quo vadis? Circ J 2010; 74: 3-12.
5. George FD. Microparticles in vascular diseases. Thromb Res 2008; 122(Suppl 1): S55-S59.
6. Ueba T, Nomura S, Inami N, Nishikawa T, Kajiwara M, Iwata R, et al. Plasma level of platelet-derived microparticles is associated with coronary heart disease risk score in healthy men. J Atheroscler Thromb 2010; 17: 342-349.
7. Langer F, Spath B, Haubold K, Holstein K, Marx G, Wierecky J, et al. Tissue factor procoagulant activity of plasma microparticles in patients with cancer-associated disseminated intravascular coagulation. Ann Hematol 2008; 87: 451-457.
8. Mallat Z, Benamer H, Hugel B, Benessiano J, Steg PG, Freyssinet JM, et al. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000; 101: 841-843.
9. Bernal-Mizrachi L, Jy W, Jimenez JJ, Pastor J, Mauro LM, Horstman LL, et al. High levels of circulating endothelial microparticles in patients with acute coronary syndromes. Am Heart J 2003; 145: 962-970.
10. Tan KT, Tayebjee MH, Lynd C, Blann AD, Lip GY. Platelet microparticles and soluble P selectin in peripheral artery disease: Relationship to extent of disease and platelet activation markers. Ann Med 2005; 37: 61-66.
11. Sabatier F, Darmon P, Hugel B, Combes V, Sanmarco M, Velut JG, et al. Type 1 and type 2 diabetic patients display different patterns of cellular microparticles. Diabetes 2002; 51: 2840-2845.
12. Porto I, De Maria GL, Di Vito L, Camaioni C, Gustapane M, Biasuccci LM. Microparticles in health and disease: Small mediators, large role? Curr Vasc Pharmacol 2011; 9: 490-500.
13. Hamilton KK, Hattori R, Esmon CT, Sims PJ. Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J Biol Chem 1990; 265: 3809-3814.
14. Combes V, Simon AC, Grau GE, Arnoux D, Camoin L, Sabatier F, et al. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest 1999; 104: 93-102.
15. Jurk K, Kehrel BE. Platelets: Physiology and biochemistry. Semin Thromb Hemost 2005; 31: 381-392.
16. Connor DE, Exner T, Ma DD, Joseph JE. The majority of circulating platelet-derived microparticles fail to bind annexin V, lack phospholipid-dependent procoagulant activity and demonstrate greater expression of glycoprotein Ib. Thromb Haemost 2010; 103: 1044-1052.
17. Huang PH, Huang SS, Chen YH, Lin CP, Chiang KH, Chen JS, et al. Increased circulating CD31+/annexin V+ apoptotic microparticles and decreased circulating endothelial progenitor cell levels in hypertensive patients with microalbuminuria. J Hypertens 2010; 28: 1655-1665.
18. Werner N, Wassmann S, Ahlers P, Kosiol S, Nickenig G. Circulating CD31+/annexin V+ apoptotic microparticles correlate with coronary endothelial function in patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2006; 26: 112-116.
19. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. Eur Heart J 2007; 28: 2525-2538.
20. Dignat-George F, Camoin-Jau L, Sabatier F, Arnoux D, Anfosso F, Bardin N, et al. Endothelial microparticles: A potential contribution to the thrombotic complications of the antiphospholipid syndrome. Thromb Haemost 2004; 91: 667-673.
21. van Ierssel SH, Van Craenenbroeck EM, Conraads VM, Van Tendeloo VF, Vrints CJ, Jorens PG, et al. Flow cytometric detection of endothelial microparticles (EMP): Effects of centrifugation and storage alter with the phenotype studied. Thromb Res 2010; 125: 332-339.
22. Monaco C, Rossi E, Milazzo D, Citterio F, Ginnetti F, D'Onofrio G, et al. Persistent systemic inflammation in unstable angina is largely unrelated to the atherothrombotic burden. J Am Coll Cardiol 2005; 45: 238-243.
23. Tan KT, Tayebjee MH, Macfadyen RJ, Lip GY, Blann AD. Elevated platelet microparticles in stable coronary artery disease are unrelated to disease severity or to indices of inflammation. Platelets 2005; 16: 368-371.
24. Leroyer AS, Tedgui A, Boulanger CM. Microparticles and type 2 diabetes. Diabetes Metab 2008; 34(Suppl 1): S27-S32.
25. Meziani F, Tesse A, Andriantsitohaina R. Microparticles are vectors of paradoxical information in vascular cells including the endothelium: Role in health and diseases. Pharmacol Rep 2008; 60: 75-84.
26. Liuzzo G, Buffon A, Biasucci LM, Gallimore JR, Caligiuri G, Vitelli A, et al. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation 1998; 98: 2370-2376.
27. Nomura S, Uehata S, Saito S, Osumi K, Ozeki Y, Kimura Y. Enzyme immunoassay detection of platelet-derived microparticles and RANTES in acute coronary syndrome. Thromb Haemost 2003; 89: 506-512.
28. Freyssinet JM, Toti F. Membrane microparticle determination: At least seeing what's being sized! J Thromb Haemost 2010; 8: 311-314.
29. Inoue T, Hikichi Y, Morooka T, Yoshida K, Fujimatsu D, Komoda H, et al. Comparison of changes in circulating platelet-derived microparticles and platelet surface P-selectin expression after coronary stent implantation. Platelets 2006; 17: 416-420.
30. Serebruany VL, Malinin AI, Jerome SD, Lowry DR, Morgan AW, Sane DC, et al. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: The Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial. Am Heart J 2003; 146: 713-720.
31. Tramontano AF, O'Leary J, Black AD, Muniyappa R, Cutaia MV, El-Sherif N. Statin decreases endothelial microparticle release from human coronary artery endothelial cells: Implication for the Rhokinase pathway. Biochem Biophys Res Commun 2004; 320: 34-38.
32. Nomura S, Shouzu A, Omoto S, Nishikawa M, Iwasaka T. Effects of losartan and simvastatin on monocyte-derived microparticles in hypertensive patients with and without type 2 diabetes mellitus. Clin Appl Thromb Hemost 2004; 10: 133-141.
33. Nozaki T, Sugiyama S, Koga H, Sugamura K, Ohba K, Matsuzawa Y, et al. Significance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk for coronary heart disease. J Am Coll Cardiol 2009; 54: 601-608.
34. Sinning JM, Losch J, Walenta K, Bohm M, Nickenig G, Werner N. Circulating CD31+/Annexin V+ microparticles correlate with cardiovascular outcomes. Eur Heart J 2011; 32: 2034-2041.
35. Morel O, Hugel B, Jesel L, Mallat Z, Lanza F, Douchet MP, et al. Circulating procoagulant microparticles and soluble GPV in myocardial infarction treated by primary percutaneous transluminal coronary angioplasty: A possible role for GPIIb-IIIa antagonists. J Thromb Haemost 2004; 2: 1118-1126.
36. Craft JA, Marsh NA. Increased generation of platelet-derived microparticles following percutaneous transluminal coronary angioplasty. Blood Coagul Fibrinolysis 2003; 14: 719-728.